Hengsai Biotechnology Wins the 13th China Innovation and Entrepreneurship Competition (Guangdong Region)

About Hengsai Bio

Founded in 2018, Hengsai Bio is a scientific and technological innovative enterprise and national high-tech enterprise dedicated to the research, development and industrialization of dendritic cell vaccines (DC vaccines). The company has successfully constructed the Eco-DCVax platform, aiming to break down the technical barriers to industrialization and develop global First-in-Class high-quality DC vaccine products with independent property rights that are safe, efficient and convenient to administer. The developed product, therapeutic dendritic cell vaccine, provides a new approach and strategy for the treatment of relapsed and refractory tumors, chronic viral infections, autoimmune diseases and other diseases that are in urgent need of effective clinical treatments.

Hengsai Bio's Shanghai R&D center will be put into operation in 2021, Zhongshan R&D center will be officially opened in October 2024, and a large R&D/production base is under construction. The company's debut pipeline, KSD-101, has successfully completed dual reporting in China and the U.S., and has been granted an IND license by the U.S. Food and Drug Administration (FDA), the first original dendritic cell vaccine (DC Vaccine) product in China to receive an IND approval from the U.S. FDA. The company has now established stable cooperative relationships with a number of domestic and foreign research institutions and tertiary hospitals to carry out clinical research and technical cooperation in order to comprehensively verify the clinical safety and efficacy of the DC vaccine.